Cargando…

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light

BACKGROUND: There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarkers that monitor neuroinflammation, neurodegeneration, treatment response, and disease progression despite treatment. OBJECTIVE: To assess the value of serum glial fibrillary acidic protein (sGFAP) as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wessels, Mark HJ, Van Lierop, Zoë YGJ, Noteboom, Samantha, Strijbis, Eva MM, Heijst, Johannes A, Van Kempen, Zoé LE, Moraal, Bastiaan, Barkhof, Frederik, Uitdehaag, Bernard MJ, Schoonheim, Menno M, Killestein, Joep, Teunissen, Charlotte E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503252/ https://www.ncbi.nlm.nih.gov/pubmed/37530045 http://dx.doi.org/10.1177/13524585231188625

Ejemplares similares

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy
por: Beerepoot, Shanice, et al.
Publicado: (2021)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
por: Coerver, Eline M. E., et al.
Publicado: (2022)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

The role of diet in multiple sclerosis onset and course: results from a nationwide retrospective birth‐year cohort
por: Loonstra, Floor C., et al.
Publicado: (2023)

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?
por: Dekker, Iris, et al.
Publicado: (2019)

Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021)

Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR
por: Noteboom, Samantha, et al.
Publicado: (2023)

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
por: Rodriguez-Mogeda, Carla, et al.
Publicado: (2023)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

Adipokines in multiple sclerosis patients are related to clinical and radiological measures
por: Loonstra, Floor C., et al.
Publicado: (2022)

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
por: Coric, Danko, et al.
Publicado: (2017)

Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis
por: Broos, Jelle Y., et al.
Publicado: (2023)

Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab
por: Mouzaki, Athanasia, et al.
Publicado: (2010)

COVID-19 in multiple sclerosis: The Dutch experience
por: Loonstra, Floor C, et al.
Publicado: (2020)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures
por: Gaetani, Lorenzo, et al.
Publicado: (2022)

Repair what is lost: Neuroprotection through neural stem cells in progressive MS
por: Schoonheim, Menno M., et al.
Publicado: (2023)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Neurofilament light chain in central nervous system infections: a prospective study of diagnostic accuracy
por: van Zeggeren, Ingeborg E., et al.
Publicado: (2022)

Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis
por: Lam, Ka-Hoo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j0egk5322v4l1t0oaevg84b71e